Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulus RNAi Candidate Can Reduce HCV Treatment To Four Weeks

Executive Summary

Although it is on FDA clinical hold to resolve safety concerns about jaundice, RG-101 has shown the ability to significantly reduce the length – and perhaps cost – of HCV therapy when combined with current direct-acting antivirals.


Related Content

Regulus HCV Candidate Is Out, But New CEO Has BD Pedigree
Regulus HCV Candidate On Clinical Hold After Second Jaundice Report
Regulus Rises On HCV Data, But Will Injection Find A Market?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts